These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3407378)

  • 1. Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients.
    Marchetti P; Benzi L; Cerri M; Cecchetti P; Giannarelli R; Giannecchini M; Di Cianni G; Cristofani R; Miccoli R; Bertolotto A
    Acta Diabetol Lat; 1988; 25(1):55-62. PubMed ID: 3407378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE; Mohideen P; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of oral folic acid on glutathione, glycaemia and lipids in Type 2 diabetes.
    Child DF; Hudson PR; Jones H; Davies GK; De P; Mukherjee S; Brain AM; Williams CP; Harvey JN
    Diabetes Nutr Metab; 2004 Apr; 17(2):95-102. PubMed ID: 15244101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma biguanide levels are correlated with metabolic effects in diabetic patients.
    Marchetti P; Benzi L; Cecchetti P; Giannarelli R; Boni C; Ciociaro D; Ciccarone AM; Di Cianni G; Zappella A; Navalesi R
    Clin Pharmacol Ther; 1987 Apr; 41(4):450-4. PubMed ID: 3829580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
    Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G
    Diabete Metab; 1994; 20(1):15-9. PubMed ID: 8056129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein lipids and apolipoproteins (AI, AII, B, CII, CIII) in type 1 and type 2 diabetes mellitus in young Kuwaiti women.
    al-Muhtaseb N; al-Yusef AR; Bajaj JS
    Diabet Med; 1991 Oct; 8(8):732-7. PubMed ID: 1838064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
    Davis TM; Cull CA; Holman RR;
    Diabetes Care; 2001 Jul; 24(7):1167-74. PubMed ID: 11423497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.
    Lalor BC; Bhatnagar D; Winocour PH; Ishola M; Arrol S; Brading M; Durrington PN
    Diabet Med; 1990; 7(3):242-5. PubMed ID: 2158410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
    Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
    Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma insulin and serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetic and non-diabetic subjects.
    Laakso M; Pyörälä K; Voutilainen E; Marniemi J
    Am J Epidemiol; 1987 Apr; 125(4):611-21. PubMed ID: 3548333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.
    Relimpio F; Pumar A; Losada F; Mangas MA; Acosta D; Astorga R
    Diabet Med; 1998 Dec; 15(12):997-1002. PubMed ID: 9868971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
    Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
    Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients.
    Taniguchi A; Nakai Y; Sakai M; Yoshii S; Hamanaka D; Hatae Y; Kawata M; Yamanouchi K; Okumura T; Doi K; Tokuyama K; Nagasaka S; Fukushima M
    Metabolism; 2002 May; 51(5):544-8. PubMed ID: 11979383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
    Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
    PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic control affects plasma lipid and apolipoprotein levels in women, but not in men, with IDDM.
    Benzi L; Marchetti P; Giampietro O; Miccoli R; Pecori N; Sanna G; Caricato F; Giovannitti MG; Ciccarone AM; Navalesi R
    Acta Diabetol Lat; 1988; 25(2):149-54. PubMed ID: 3223190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.